Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
FIGURE: 1 / 2
Rituximab Antibody (A01969-40) in ELISA
Standard curve of Rituximab Sandwich ELISA. The Rituximab Sandwich ELISA assay is developed by using Anti-Rituximab Antibody (6C1), mAb, Mouse (GenScript, A01969-40) and Anti-Rituximab Antibody (17B6), mAb, Mouse (GenScript, A01970-40) as the capture and detection antibodies, respectively. In this ELISA assay, Anti-Rituximab Antibody (17B6), mAb, Mouse (GenScript, A01970-40) was labeled with Biotin. GenScript can provide customized conjugation services for this product per customer's request. The Sensitivity is less than 1 ng/mL.
Product Details
A01969-40
Product Specifications
Species Reactivity
Chemical
Host/Isotype
Mouse
/ IgG1
Class
Monoclonal
Type
Antibody
Clone
6C1
Immunogen
Rituximab
Conjugate
Form
Lyophilized
Purification
Protein A
Storage buffer
PBS, pH 7.4
Contains
0.02% sodium azide
Storage conditions
-20°C or -80°C if preferred
Shipping conditions
Ambient (domestic); Wet ice (international)
Product Specific Information
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
Rituximab (Rituxan) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of hematological cancers and autoimmune diseases. When Rituximab binds to CD20 on the surface of normal and malignant B cells, natural killer (NK) cells is activated to destroy these B cells. It is therefore used to treat diseases with too many B cells, overactive B cells, or dysfunctional B cells. Anti-Rituximab Antibody (6C1), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Rituximab.
Target Information
Rituximab (Rituxan) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with certain autoimmune diseases and types of cancer, such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, idiopathic thrombocytopenic purpura, and pemphigus vulgaris. Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein it triggers cell death.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Bioinformatics
Protein Aliases: IDEC-C2B8; Rituxan
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support